Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis

Abstract EN

Objectives.

Osteopontin (OPN) is overexpressed in breast cancers, while its clinical and prognostic significance remained unclear.

This study aimed to assess the prognostic value of OPN, especially its splice variants, in breast cancers.

Methods.

Data were extracted from eligible studies concerning the OPN and OPN-c expression in breast cancer patients and were used to calculate the association between OPN/OPN-c and survival.

Two reviewer teams independently screened the literatures according to the inclusion and exclusion criteria based on quality evaluation.

Following the processes of data extraction, assessment, and transformation, meta-analysis was carried out via RevMan 5.3 software.

Results.

A total of ten studies involving 1,567 patients were included.

The results demonstrated that high level OPN indicated a poor outcome in the OS (HR = 2.22, 95% CI: 1.23–4.00, and P = 0.008 ; random-effects model) with heterogeneity ( I 2 = 62 %) of breast cancer patients.

High level OPN-c appeared to be more significantly associated with poor survival (HR = 2.14, 95% CI: 1.51–3.04, and P < 0.0001 ; fixed-effects model) with undetected heterogeneity ( I 2 = 0 %).

Conclusions.

Our analyses indicated that both OPN and OPN-c could be considered as prognostic markers for breast cancers.

The high level of OPN-c was suggested to be more reliably associated with poor survival in breast cancer patients.